Introduction by the moderator - Martine Rémy-Jardin, Lille / FR
04:00
2
Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients - Gianluca Milanese, Parma / IT
08:00
3
Evaluation of differential response in patients with metastatic lung cancer treated with immune checkpoint inhibitors: a pilot study - Andreu Antolín Redondo, Barcelona / ES
08:00
4
Comparison of performance by whole-body MRI, PET/MRI and PET/CT and conventional staging methods for TNM and VALSG staging of small cell carcinoma patients - Yoshiharu Ohno, Toyoake / JP
08:00
5
To differentiate pulmonary sclerosing pneumocytoma from atypical lung cancer based-on contrast-enhanced CT: a radiomic analysis - Lei Wang, Nanchang / CN
08:00
6
Differentiation of benign lung nodules and lung metastases: a radiomics approach in a large cancer patient cohort - Simon Lennartz, Köln / DE